Supply Chain Intelligence

Rallybio Corporation Supply Chain

RLYB supply chain intelligence for Rallybio Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

RLYB ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

10Suppliers
17Customers
1Debt Items
20Related Chains

Source-Backed Evidence Depth

Rallybio Corporation (RLYB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

29Total relationships
5Distinct source URLs
10High confidence
0.741Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Rallybio Corporation Suppliers

TickerNameConfidenceEvidence
AVENZO AVENZO 90% a termination fee of $600,000 may be payable by Rallybio to Avenzo if (i)(a) the Merger Agreement is terminated because the Merger has not been consummated by the End Date
CANDID CANDID 90% On March 1, 2026, Rallybio entered into an Agreement and Plan of Merger and Reorganization with Candid pursuant to which the parties intended to undertake a business combination.
CANDID-THERAPEUTICS-INC CANDID-THERAPEUTICS-INC 90% Candid and UCB, on behalf of themselves and their respective affiliates, agreed to release Parent and its affiliates from all claims in respect of the Merger Agreement, the Contemplated Transactions …
SANOFI SANOFI 90% We paid Sanofi an upfront cash payment of $3.0 million.
UCB-S-A UCB-S-A 90% Candid and UCB, on behalf of themselves and their respective affiliates, agreed to release Parent and its affiliates from all claims in respect of the Merger Agreement, the Contemplated Transactions …
SOBI SOBI 85% we entered into an agreement with Sobi, pursuant to which we acquired the right, title and interest in assets related to certain C5 inhibitor compounds.
JNJ Johnson & Johnson 72% any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shal…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from RLYB graph: any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the…
SNYNF Sanofi 72% any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shal…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from RLYB graph: any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing t…

Rallybio Corporation Customers

TickerNameConfidenceEvidence
JJDC JJDC 92% The Company recognized revenue of $ 0.2 million for both the three months ended March 31, 2026 and 2025, related to data collection and data submission with the identified performance obligations, an…
AVENZO AVENZO 85% Pursuant to the Subscription Agreement, and subject to the terms and conditions therein, Avenzo agreed to sell, and the Investors agreed to purchase, immediately prior to the Effective Time, shares o…
JNJ Johnson & Johnson 72% any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shal…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from RLYB graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from RLYB graph: Reciprocal relationship from JNJ grap…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from RLYB graph: ompany determined that the J&J Collaboration Agreement is not in the scope of ASC 808. Asset Acquisition In May 2022…
SNYNF Sanofi 72% ompany determined that the J&J Collaboration Agreement is not in the scope of ASC 808. Asset Acquisition In May 2022, we obtained worldwide exclusive rights to RLYB331, with Kymab Limited ("Sanofi") …
ABCELLERA-BIOLOGICS-INC ABCELLERA-BIOLOGICS-INC 62% iance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration combined AbCellera Biologics Inc.'s ("AbCellera's") anti…
ALEXION-PHARMACEUTICALS-INC ALEXION-PHARMACEUTICALS-INC 62% or proceedings with a low probability of success might be initiated and require significant resources and management attention to defend. The risks of being involved in such litigation and proceeding…
COMPANY-LLC COMPANY-LLC 62% s; ▪ costs related to manufacturing material for our clinical trials, including expenses related to the manufacturing scale-up and fees paid to contract manufacturing organizations ("CMOs"); 89 T a b…
COORDINATION-GROUP COORDINATION-GROUP 62% sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shall ne…
EMERGING-GROWTH-COMPANY EMERGING-GROWTH-COMPANY 62% ay 2026, we received a $50.0 million Parent Termination Fee in connection with the termination of the Merger Agreement. As of March 31, 2026, we had $46.8 million of cash, cash equivalents and market…
KYMAB-LIMITED KYMAB-LIMITED 62% ASC 808, Collaborative Arrangements . F-15 T a b le of Contents Asset Acquisition In May 2022, we obtained worldwide exclusive rights to RLYB331, with Kymab Limited ("Sanofi") a preclinical antibody.…
MOMENTA-PHARMACEUTICALS-INC MOMENTA-PHARMACEUTICALS-INC 62% sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shall ne…
NASDAQ-STOCK-MARKET-LLC NASDAQ-STOCK-MARKET-LLC 62% . Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but su…
RECURSION-EXSCIENTIA-VENTURES-I-INC RECURSION-EXSCIENTIA-VENTURES-I-INC 62% sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shall ne…
RE-VENTURES-I-LLC RE-VENTURES-I-LLC 62% e-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficia…
USA-LLC USA-LLC 62% ices; 23 Table of Contents ▪ costs related to manufacturing material for our clinical trials, including expenses related to the manufacturing scale-up and fees paid to contract manufacturing organiza…

Rallybio Corporation Debt Obligations

InstrumentDescriptionConfidenceEvidence
RLYB-DEBT Debt stack $154,000 90% Market cache reports total debt of $154,000.

Rallybio Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Rallybio Corporation.

Rallybio Corporation Ownership

HolderNameConfidenceEvidence
RLYB-OWNER-JOHNSON-JOHNSON JOHNSON & JOHNSON 90% 13F overlay lists JOHNSON & JOHNSON as top holder; 3 tracked holders.

Rallybio Corporation Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DSGN Design Therapeutics, Inc. 100.00 2
CSTE Caesarstone Ltd. 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
BLRX BioLineRx Ltd. 100.00 2
AZN AstraZeneca PLC 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
AORT Artivion, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
BLLN BillionToOne, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Rallybio Corporation.

Unlock full RLYB data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
RLYB
Unlock RLYB Supply Chain Data
Verified relationships include:
AVENZOAVENZOSupplier90%
CANDIDCANDIDSupplier90%
JJDCJJDCCustomer92%
AVENZOAVENZOCustomer85%
+25 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →